Asia Pacific Brain Cancer Diagnostic Market
市场规模（十亿美元）
CAGR :
% 
USD
347.77 Million
USD
1,489.35 Million
2022
2030
 Forecast Period |
2023 –2030 |
 Market Size (Base Year) |
USD 347.77 Million |
 Market Size (Forecast Year) |
USD 1,489.35 Million |
 CAGR |
% |
| Major Markets Players |
亚太脑癌诊断市场，按测试类型（影像学测试、活检、腰椎穿刺、分子测试、脑电图等）、癌症类型（听神经瘤、星形细胞瘤、多形性胶质母细胞瘤、脑膜瘤、少突胶质细胞瘤等）、年龄组（21 岁以下、21-34 岁、35-65 岁和 65 岁以上）、最终用户（医院、专科诊所、诊断中心和研究机构、门诊手术中心等）、行业趋势和预测到 2030 年。
亚太脑癌诊断市场分析及规模
推动脑癌诊断市场增长的主要因素之一是全球脑癌病例的增加。多家公司为寻求更好的治疗方法而进行的持续临床试验研究推动了市场扩张。市场还受到人们对脑癌早期诊断认识的提高和脑癌细胞药物输送创新的影响。然而，脑癌诊断和治疗的高成本、脑癌诊断较晚导致预后不良以及治疗药物和疗法的副作用成为预测期内亚太脑癌诊断市场发展的制约因素。
另一方面，新兴企业不断增加的投资和资金、政府对癌症诊断的举措以及不断增加的医疗支出为市场增长提供了机遇。然而，诊断产品的严格监管要求和开展诊断测试所面临的运营障碍为亚太地区脑癌诊断市场带来了挑战。
由于成像技术的进步，亚太地区对脑癌诊断产品的需求将会增加。各公司正在采取举措，逐步推动市场增长。
亚太地区脑癌诊断市场预计将在 2023 年至 2030 年的预测期内实现市场增长。Data Bridge Market Research 分析称，在 2023 年至 2030 年的预测期内，该市场将以 20.0% 的复合年增长率增长，预计到 2030 年将从 2022 年的 3.4777 亿美元达到 14.8935 亿美元。
|
报告指标 |
细节 |
|
预测期 |
2023 至 2030 年 |
|
基准年 |
2022 |
|
历史岁月 |
2021 (可定制为 2020-2016) |
|
定量单位 |
收入（百万美元） |
|
涵盖的领域 |
测试类型（影像学测试、活检、腰椎穿刺、分子检测、脑电图等）、癌症类型（听神经瘤、星形细胞瘤、多形性胶质母细胞瘤、脑膜瘤、少突胶质细胞瘤等）、年龄组（21 岁以下、21-34 岁、35-65 岁和 65 岁及以上）、最终用户（医院、专科诊所、诊断中心和研究机构、门诊手术中心等）。 |
|
覆盖国家 |
中国、日本、韩国、印度、澳大利亚、新加坡、泰国、马来西亚、印度尼西亚、菲律宾和亚太其他地区 |
|
涵盖的市场参与者 |
日本光电株式会社、佳能公司、富士胶片控股株式会社、东软集团、通用电气医疗集团、荷兰皇家飞利浦电子公司、BD 和 FONAR 公司等 |
市场定义
脑癌是脑细胞过度生长形成的肿块，称为肿瘤。这是一种脑部疾病，癌细胞（恶性细胞）出现在脑组织中。癌细胞繁殖产生大量癌组织（肿瘤），干扰大脑功能，如肌肉控制、感觉、记忆和其他身体功能。来自脑组织的癌细胞称为原发性脑肿瘤，而从其他身体部位扩散到脑部的肿瘤称为转移性或继发性脑肿瘤。
原发性脑肿瘤可由各种脑组织（例如，神经胶质细胞、星形胶质细胞和其他脑细胞类型）发展而来。转移性脑癌是由癌细胞从身体器官扩散到大脑引起的。
亚太脑癌诊断市场动态
本节旨在了解市场驱动因素、机遇、限制因素和挑战。下文将详细讨论所有这些内容：
驱动程序
- 全球脑癌病例不断增加
在身体其他部位发展并扩散到大脑的癌症被称为继发性脑肿瘤或脑转移。有多种癌症可以转移到大脑，例如乳腺癌、肺癌、结肠癌和肾癌。脑癌细胞通常不会扩散到大脑之外。相反，它们有能力在大脑内短距离移动。通过家族祖先遗传的遗传联系、接触某些工业化学品或溶剂、免疫系统受损以及之前的放射治疗可能是导致脑癌的一些主要原因。
全球范围内脑癌病例正在增加。根据美国国家癌症研究所的报告，2019 年美国估计有 176,566 人患有脑癌和其他神经系统癌症。此外，根据 2017-2019 年的数据，预计约有 0.6% 的男性和女性将在其一生中的某个时刻被诊断出患有脑癌和其他神经系统癌症。
- 提高对脑癌早期诊断的认识
五月份是美国全国范围内的脑癌宣传月。该宣传月的重点是将脑瘤社区聚集在一起，提高患者群体的认知度。
脑癌并不像其他类型的癌症一样常见。然而，治疗脑癌的新方法和创新方法更为重要。根据研究，全球有 140 万患者患有恶性脑瘤，到今年年底，另有 256,000 人将被诊断出患有恶性脑瘤。
由于 COVID-19 在全球范围内的影响，患者护理、教育和癌症研究的重要性变得越来越明显。从未来来看，在为脑癌患者发现新药和有效治疗方法方面还有更多的基础工作要做。脑癌宣传月是一项完全致力于这些努力的运动，即使在疫情期间也是如此。
机会
- 新兴企业加大投资和融资
脑癌市场巨大，受该疾病影响的人口数量不断增加，吸引了其他参与者进入该疾病的诊断领域。早期诊断脑癌是一项繁琐的任务，但借助新的疾病诊断产品线，可以实现这一目标。
该行业提供了众多增长机会。因此，许多提供创新产品和技术的初创公司纷纷进入市场。许多新公司和初创公司都对脑癌领域充满期待。他们正试图扩大业务并增加新上市产品的分销。以下列出了一些公司，预计它们将成为脑癌诊断的机会。
- 政府针对癌症诊断的举措
政府在应对癌症方面发挥着重要作用，因为癌症是全球主要疾病。过去几十年来，癌症在人类中增长非常迅速。2018 年亚太地区有 9,555,027 例死亡病例归因于癌症，其中 241,037 例（2.71%）属于脑癌。
全球各国政府都在积极采取多项措施应对癌症，尤其是脑癌诊断，以提高人们对癌症的认识。政府和非政府组织为治疗导向的生物学和药物开发提供了 57% 的资金，其中 7% 用于预防，13% 用于癌症的早期检测、诊断和预后。这些政府针对癌症诊断的举措正在推动市场的需求。
限制/挑战
- 脑癌诊断和治疗费用高昂
大脑是我们身体最重要的部分，是产生记忆和情感的器官，也是我们技能和专长的载体。因此，脑癌具有独特的破坏性。脑瘤可导致认知、行为和个性的改变，造成高昂的经济成本，这些成本由个人、卫生系统（直接医疗成本）和更广泛的公共财政（直接非医疗成本和间接成本）承担。
西方国家脑肿瘤手术的平均费用非常高。每种治疗相关的费用将根据具体程序、位置和肿瘤严重程度而有所不同。《癌症》杂志发表的一项研究发现，脑癌患者及其家庭承担的经济负担明显高于其他类型癌症患者。脑癌患者的间接费用最高，平均每年 64,790 美元。因此，与脑癌诊断和治疗相关的高成本可能会抑制市场增长。
- 开展诊断测试时面临的操作障碍
脑癌诊断领域的最新进展可能与试剂盒、仪器、试剂、对照或其他任何方面有关。随着技术的进步，改变医疗保健专业人员的适应性并不容易。为了在诊断中做出结构性决策和精确结果，组织需要对医疗保健专业人员进行培训，以克服和避免诊断错误。
不同地区的农村、发展中国家和低收入国家没有足够的基础设施来维护新试剂盒和样本储存。这是因为电力供应有限，以及医疗专业人员缺乏处理新试剂盒和试剂的教育和意识。这会导致诊断结果错误，并可能导致某些死亡，并可能对执行测试的个人的携带者构成威胁。
这些与开展癌症诊断测试相关的障碍可能会影响人们的生活。对于低收入国家来说，这是最难克服的部分之一。因此，这影响了诊断界，并对亚太地区脑癌诊断市场构成了挑战。
后新冠疫情对亚太脑癌诊断市场的影响
COVID-19 疫情对脑癌诊断和外科手术行业产生了巨大影响。癌症诊断产品行业的贸易团体声称，亚太地区诊断产品供应链已严重受损，影响了脑癌诊断市场的终端用户消费。由于物流和运输问题，2020 年第一季度诊断产品的销售大幅延迟。在需求方面，由于封锁结束后人们必须接受诊断，市场正在增长。需要考虑这种情况，并需要进行紧急诊断。此外，在供应方面，市场的增长呈负增长。这是由于许多生产诊断、手术和癌症护理仪器的国家处于封锁状态。
由于亚太地区爆发新冠肺炎疫情，诊断产品供应受到重创。供应减少的主要原因是世界各国采取了各种检疫政策。这与行动限制和劳动力减少是诊断仪器跟踪系统供应市场呈下降趋势的主要原因。这极大地影响了医疗器械的质量和功效。许多国家现有的产品出口政策导致供需比例失衡。由于新冠肺炎疫情导致劳动力人数减少是导致脑癌诊断产品供应减少的另一个因素。
最新动态
- 2022 年 11 月，西门子医疗有限公司推出了两款专为临床和科学用途而设计的最新磁共振断层扫描仪。由于其高场强和强大的梯度性能，这两款扫描仪将成为更清晰地检测身体最精细结构的最佳选择。
- 2022 年 11 月，BD 宣布向 Valley-Mount Sinai Comprehensive Cancer Care 拨款 652,000 美元，以增加癌症临床试验的多样性、公平性和包容性。
亚太脑癌诊断市场范围
亚太脑癌诊断市场细分为检测类型、癌症类型、年龄组和最终用户。这些细分市场之间的增长将帮助您分析行业中增长微弱的细分市场，并为用户提供有价值的市场概览和市场洞察，以便做出战略决策，确定核心市场应用。
测试类型
- 影像学检查
- 活检
- 腰椎穿刺
- 分子检测
- 脑电图 (EEG)
- 其他的
根据测试类型，亚太脑癌诊断市场分为影像学测试、活检、腰椎穿刺、分子测试、脑电图 (EEG) 等。
癌症类型
- 听神经瘤
- 星形细胞瘤
- 多形性胶质母细胞瘤
- 脑膜瘤
- 少突胶质细胞瘤
- 其他的
根据癌症类型，亚太脑癌诊断市场分为听神经瘤、星形细胞瘤、多形性胶质母细胞瘤、脑膜瘤、少突胶质细胞瘤等。
年龄组
- 21岁以下
- 21-35
- 35-65
- 65 岁及以上
根据年龄组，亚太脑癌诊断市场细分为21岁以下、21-34岁、35-65岁和65岁以上。
最终用户
- 医院
- 专科诊所
- 诊断中心和研究机构
- 门诊手术中心
- 其他的
根据最终用户，亚太脑癌诊断市场分为医院、专科诊所、诊断中心、研究机构、门诊手术中心等。
亚太脑癌诊断市场区域分析/见解
对亚太脑癌诊断市场进行了分析，并按国家、测试类型、癌症类型、年龄组和最终用户提供了市场规模洞察和趋势。
亚太脑癌诊断市场包括中国、日本、韩国、印度、澳大利亚、新加坡、泰国、马来西亚、印度尼西亚、菲律宾和亚太其他地区。
2023 年，由于消费者对脑癌诊断益处的认识不断提高，预计中国将主导亚太脑癌诊断市场。预测期内，脑癌诊断产品需求的增加以及行业研发活动的增加也有望推动市场发展。
竞争格局和亚太脑癌诊断市场份额分析
脑癌诊断市场竞争格局提供了竞争对手的详细信息。详细信息包括公司概况、公司财务状况、产生的收入、市场潜力、研发投资、新市场计划、亚太地区业务、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度以及应用主导地位。以上提供的数据点仅与专注于亚太脑癌诊断市场的公司有关。
该市场的一些主要参与者包括日本光电株式会社、佳能公司、富士胶片控股株式会社、东软集团、通用电气医疗集团、荷兰皇家飞利浦电子公司、BD 和 FONAR 公司等。
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
目录
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE ASIA PACIFIC BRAIN CANCER DIAGNOSTIC MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 ASIA PACIFIC BRAIN CANCER DIAGNOSTIC MARKET: SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 PRODUCT TYPE SEGMENT LIFELINE CURVE
2.8 DBMR MARKET POSITION GRID
2.9 VENDOR SHARE ANALYSIS
2.1 MARKET END USER COVERAGE GRID
2.11 SECONDARY SOURCES
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER’S FIVE FORCES
5 EPIDEMIOLOGY
6 ASIA PACIFIC BRAIN CANCER DIAGNOSTIC MARKET, INDUSTRY INSIGHT
7 ASIA PACIFIC BRAIN CANCER DIAGNOSTIC MARKET, REGULATIONS
7.1 REGULATORY SCENARIO IN THE U.S
7.2 REGULATORY SCENARIO IN AUSTRALIA
7.3 REGULATORY SCENARIO IN JAPAN
7.4 REGULATORY SCENARIO IN CHINA
8 MARKET OVERVIEW
8.1 DRIVERS
8.1.1 RISING CASES OF BRAIN CANCER WORLDWIDE
8.1.2 RISING AWARENESS OF THE EARLY DIAGNOSIS OF BRAIN CANCER
8.1.3 IMPROVED IMAGING TECHNIQUES
8.1.4 INNOVATIONS IN DRUG DELIVERY TO BRAIN CANCER CELLS
8.2 RESTRAINTS
8.2.1 HIGH COST ASSOCIATED WITH DIAGNOSIS & TREATMENT FOR BRAIN CANCER
8.2.2 SIDE EFFECTS OF BRAIN CANCER TREATMENT DRUGS & THERAPIES
8.2.3 LATE DIAGNOSIS OF BRAIN CANCER RESULTING IN POOR PROGNOSIS
8.3 OPPORTUNITIES
8.3.1 INCREASING INVESTMENT AND FUNDING BY EMERGING PLAYERS
8.3.2 GOVERNMENT INITIATIVES TOWARD CANCER DIAGNOSTIC
8.3.3 RISING HEALTHCARE EXPENDITURE
8.4 CHALLENGES
8.4.1 STRINGENT REGULATORY REQUIREMENTS FOR DIAGNOSTIC PRODUCTS
8.4.2 OPERATIONAL BARRIERS FACED IN CONDUCTING DIAGNOSTIC TESTS
9 ASIA PACIFIC BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE
9.1 OVERVIEW
9.2 IMAGING TEST
9.2.1 CT SCAN
9.2.2 MRI
9.2.3 PET
9.2.4 OTHERS
9.3 MOLECULAR TESTING
9.4 ELECTROENCEPHALOGRAPHY (EEG)
9.5 LUMBAR PUNCTURE
9.6 BIOPSY
9.6.1 OPEN BIOPSY
9.6.2 STEREOTACTIC BIOPSY
9.6.3 NEEDLE BIOPSY
9.6.4 NEUROENDOSCOPY
9.7 OTHERS
10 ASIA PACIFIC BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE
10.1 OVERVIEW
10.2 GLIOBLASTOMA MULTIFORME
10.3 MENINGIOMAS
10.4 ASTROCYTOMAS
10.5 ACOUSTIC NEUROMA
10.6 OLIGODENDROGLIOMA
10.7 OLIGODENDROGLIOMA
10.8 OTHERS
11 ASIA PACIFIC BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP
11.1 OVERVIEW
11.2 35-65
11.3 65 AND ABOVE
11.4 BELOW 21
11.5 21-34
12 ASIA PACIFIC BRAIN CANCER DIAGNOSTIC MARKET, BY END USER
12.1 OVERVIEW
12.2 HOSPITALS
12.3 SPECIALTY CLINICS
12.4 DIAGNOSTIC CENTERS & RESEARCH INSTITUTES
12.5 AMBULATORY SURGICAL CENTERS
12.6 OTHERS
13 ASIA PACIFIC BRAIN CANCER DIAGNOSTIC MARKET, BY REGION
13.1 ASIA-PACIFIC
13.1.1 CHINA
13.1.2 JAPAN
13.1.3 INDIA
13.1.4 AUSTRALIA
13.1.5 SOUTH KOREA
13.1.6 THAILAND
13.1.7 SINGAPORE
13.1.8 INDONESIA
13.1.9 MALAYSIA
13.1.10 PHILIPPINES
13.1.11 REST OF ASIA-PACIFIC
14 ASIA PACIFIC BRAIN CANCER DIAGNOSTIC MARKET: COMPANY LANDSCAPE
14.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC
15 SWOT ANALYSIS
16 ASIA PACIFIC BRAIN CANCER DIAGNOSTIC MARKET, COMPANY PROFILE
16.1 KONINKLIJKE PHILIPS N.V.
16.1.1 COMPANY SNAPSHOT
16.1.2 REVENUE ANALYSIS
16.1.3 COMPANY SHARE ANALYSIS
16.1.4 PRODUCT PORTFOLIO
16.1.5 RECENT DEVELOPMENTS
16.2 CANON INC.
16.2.1 COMPANY SNAPSHOT
16.2.2 REVENUE ANALYSIS
16.2.3 COMPANY SHARE ANALYSIS
16.2.4 PRODUCT PORTFOLIO
16.2.5 RECENT DEVELOPMENT
16.3 SIEMENS HEALTHCARE GMBH
16.3.1 COMPANY SNAPSHOT
16.3.2 REVENUE ANALYSIS
16.3.3 COMPANY SHARE ANALYSIS
16.3.4 PRODUCT PORTFOLIO
16.3.5 RECENT DEVELOPMENTS
16.4 BD
16.4.1 COMPANY SNAPSHOT
16.4.2 REVENUE ANALYSIS
16.4.3 COMPANY SHARE ANALYSIS
16.4.4 PRODUCT PORTFOLIO
16.4.5 RECENT DEVELOPMENTS
16.5 NIHON KOHDEN CORPORATION.
16.5.1 COMPANY SNAPSHOT
16.5.2 RECENT FINANCIALS
16.5.3 COMPANY SHARE ANALYSIS
16.5.4 PRODUCT PORTFOLIO
16.5.5 RECENT DEVELOPMENT
16.6 BIOCEPT, INC.
16.6.1 COMPANY SNAPSHOT
16.6.2 REVENUE ANALYSIS
16.6.3 PRODUCT PORTFOLIO
16.6.4 RECENT DEVELOPMENT
16.7 BIOMIND
16.7.1 COMPANY SNAPSHOT
16.7.2 PRODUCT PORTFOLIO
16.7.3 RECENT DEVELOPMENT
16.8 CEREBRAL DIAGNOSTIC
16.8.1 COMPANY SNAPSHOT
16.8.2 PRODUCT PORTFOLIO
16.8.3 RECENT DEVELOPMENT
16.9 DXCOVER LIMITED
16.9.1 COMPANY SNAPSHOT
16.9.2 PRODUCT PORTFOLIO
16.9.3 RECENT DEVELOPMENT
16.1 FONAR CORP.
16.10.1 COMPANY SNAPSHOT
16.10.2 REVENUE ANALYSIS
16.10.3 PRODUCT PORTFOLIO
16.10.4 RECENT DEVELOPMENT
16.11 FUJIFILM CORPORATION
16.11.1 COMPANY SNAPSHOT
16.11.2 REVENUE ANALYSIS
16.11.3 PRODUCT PORTFOLIO
16.11.4 RECENT DEVELOPMENT
16.12 GE HEALTHCARE.
16.12.1 COMPANY SNAPSHOT
16.12.2 REVENUE ANALYSIS
16.12.3 PRODUCT PORTFOLIO
16.12.4 RECENT DEVELOPMENT
16.13 HITACHI, LTD.
16.13.1 COMPANY SNAPSHOT
16.13.2 REVENUE ANALYSIS
16.13.3 PRODUCT PORTFOLIO
16.13.4 RECENT DEVELOPMENT
16.14 MINFOUND MEDICAL SYSTEMS CO.,
16.14.1 COMPANY SNAPSHOT
16.14.2 PRODUCT PORTFOLIO
16.14.3 RECENT DEVELOPMENT
16.15 NANTOMICS.
16.15.1 COMPANY SNAPSHOT
16.15.2 PRODUCT PORTFOLIO
16.15.3 RECENT DEVELOPMENT
16.16 NEUSOFT CORPORATION
16.16.1 COMPANY SNAPSHOT
16.16.2 REVENUE ANALYSIS
16.16.3 PRODUCT PORTFOLIO
16.16.4 RECENT DEVELOPMENT
16.17 SEQUOIA HEALTHCARE.
16.17.1 COMPANY SNAPSHOT
16.17.2 PRODUCT PORTFOLIO
16.17.3 RECENT DEVELOPMENT
16.18 STERNMED GMBH
16.18.1 COMPANY SNAPSHOT
16.18.2 PRODUCT PORTFOLIO
16.18.3 RECENT DEVELOPMENT
16.19 THERMO FISHER SCIENTIFIC INC.
16.19.1 COMPANY SNAPSHOT
16.19.2 REVENUE ANALYSIS
16.19.3 PRODUCT PORTFOLIO
16.19.4 RECENT DEVELOPMENT
16.2 TIME MEDICAL HOLDING.
16.20.1 COMPANY SNAPSHOT
16.20.2 PRODUCT PORTFOLIO
16.20.3 RECENT DEVELOPMENTS
17 QUESTIONNAIRE
18 RELATED REPORTS
表格列表
TABLE 1 ASIA PACIFIC BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 2 ASIA PACIFIC IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 3 ASIA PACIFIC IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 4 ASIA PACIFIC MOLECULAR TESTING IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 5 ASIA PACIFIC ELECTROENCEPHALOGRAPHY (EEG) IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 6 ASIA PACIFIC LUMBAR PUNCTURE IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 7 ASIA PACIFIC BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 8 ASIA PACIFIC BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 9 ASIA PACIFIC OTHERS IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 10 ASIA PACIFIC BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 11 ASIA PACIFIC GLIOBLASTOMA MULTIFORME IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 12 ASIA PACIFIC MENINGIOMAS IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 13 ASIA PACIFIC ASTROCYTOMAS IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 14 ASIA PACIFIC ACOUSTIC NEUROMA IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 15 ASIA PACIFIC OLIGODENDROGLIOMA IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 16 ASIA PACIFIC OTHERS IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 17 ASIA PACIFIC BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 18 ASIA PACIFIC 35-65 IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 19 ASIA PACIFIC 65 AND ABOVE IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 20 ASIA PACIFIC BELOW 21 IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 21 ASIA PACIFIC 21-34 IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 22 ASIA PACIFIC BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 23 ASIA PACIFIC HOSPITALS IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 24 ASIA PACIFIC SPECIALTY CLINICS IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 25 ASIA PACIFIC DIAGNOSTIC CENTERS & RESEARCH INSTITUTES IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 26 ASIA PACIFIC AMBULATORY SURGICAL CENTERS IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 27 ASIA PACIFIC OTHERS IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 28 ASIA-PACIFIC BRAIN CANCER DIAGNOSTIC MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
TABLE 29 ASIA-PACIFIC BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 30 ASIA-PACIFIC IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 31 ASIA-PACIFIC BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 32 ASIA-PACIFIC BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 33 ASIA-PACIFIC BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 34 ASIA-PACIFIC BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 35 CHINA BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 36 CHINA IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 37 CHINA BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 38 CHINA BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 39 CHINA BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 40 CHINA BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 41 JAPAN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 42 JAPAN IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 43 JAPAN BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 44 JAPAN BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 45 JAPAN BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 46 JAPAN BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 47 INDIA BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 48 INDIA IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 49 INDIA BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 50 INDIA BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 51 INDIA BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 52 INDIA BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 53 AUSTRALIA BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 54 AUSTRALIA IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 55 AUSTRALIA BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 56 AUSTRALIA BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 57 AUSTRALIA BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 58 AUSTRALIA BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 59 SOUTH KOREA BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 60 SOUTH KOREA IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 61 SOUTH KOREA BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 62 SOUTH KOREA BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 63 SOUTH KOREA BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 64 SOUTH KOREA BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 65 THAILAND BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 66 THAILAND IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 67 THAILAND BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 68 THAILAND BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 69 THAILAND BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 70 THAILAND BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 71 SINGAPORE BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 72 SINGAPORE IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 73 SINGAPORE BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 74 SINGAPORE BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 75 SINGAPORE BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 76 SINGAPORE BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 77 INDONESIA BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 78 INDONESIA IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 79 INDONESIA BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 80 INDONESIA BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 81 INDONESIA BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 82 INDONESIA BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 83 MALAYSIA BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 84 MALAYSIA IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 85 MALAYSIA BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 86 MALAYSIA BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 87 MALAYSIA BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 88 MALAYSIA BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 89 PHILIPPINES BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 90 PHILIPPINES IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 91 PHILIPPINES BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 92 PHILIPPINES BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 93 PHILIPPINES BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 94 PHILIPPINES BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 95 REST OF ASIA-PACIFIC BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
图片列表
FIGURE 1 ASIA PACIFIC BRAIN CANCER DIAGNOSTIC MARKET: SEGMENTATION
FIGURE 2 ASIA PACIFIC BRAIN CANCER DIAGNOSTIC MARKET: DATA TRIANGULATION
FIGURE 3 ASIA PACIFIC BRAIN CANCER DIAGNOSTIC MARKET: DROC ANALYSIS
FIGURE 4 ASIA PACIFIC BRAIN CANCER DIAGNOSTIC MARKET: ASIA PACIFIC VS REGIONAL MARKET ANALYSIS
FIGURE 5 ASIA PACIFIC BRAIN CANCER DIAGNOSTIC MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 ASIA PACIFIC BRAIN CANCER DIAGNOSTIC MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 ASIA PACIFIC BRAIN CANCER DIAGNOSTIC MARKET: DBMR POSITION GRID
FIGURE 8 ASIA PACIFIC BRAIN CANCER DIAGNOSTIC MARKET: VENDOR SHARE ANALYSIS
FIGURE 9 ASIA PACIFIC BRAIN CANCER DIAGNOSTIC MARKET: END USER COVERAGE GRID
FIGURE 10 ASIA PACIFIC BRAIN CANCER DIAGNOSTIC MARKET: SEGMENTATION
FIGURE 11 RISING CASES OF BRAIN CANCER WORLDWIDE & IMPROVED IMAGING TECHNIQUES ARE EXPECTED TO DRIVE THE ASIA PACIFIC BRAIN CANCER DIAGNOSTIC MARKET FROM 2023 TO 2030
FIGURE 12 THE IMAGING TEST SEGMENT IS EXPECTED TO HAVE THE LARGEST SHARE OF THE ASIA PACIFIC BRAIN CANCER DIAGNOSTIC MARKET FROM 2023 TO 2030
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF THE ASIA PACIFIC BRAIN CANCER DIAGNOSTIC MARKET
FIGURE 14 ASIA PACIFIC BRAIN CANCER DIAGNOSTIC MARKET: BY TEST TYPE, 2022
FIGURE 15 ASIA PACIFIC BRAIN CANCER DIAGNOSTIC MARKET: BY TEST TYPE 2023-2030 (USD MILLION)
FIGURE 16 ASIA PACIFIC BRAIN CANCER DIAGNOSTIC MARKET: BY TEST TYPE, CAGR (2023-2030)
FIGURE 17 ASIA PACIFIC BRAIN CANCER DIAGNOSTIC MARKET: BY TEST TYPE, LIFELINE CURVE
FIGURE 18 ASIA PACIFIC BRAIN CANCER DIAGNOSTIC MARKET: BY CANCER TYPE, 2022
FIGURE 19 ASIA PACIFIC BRAIN CANCER DIAGNOSTIC MARKET: BY CANCER TYPE 2023-2030 (USD MILLION)
FIGURE 20 ASIA PACIFIC BRAIN CANCER DIAGNOSTIC MARKET: BY CANCER TYPE, CAGR (2023-2030)
FIGURE 21 ASIA PACIFIC BRAIN CANCER DIAGNOSTIC MARKET: BY CANCER TYPE, LIFELINE CURVE
FIGURE 22 ASIA PACIFIC BRAIN CANCER DIAGNOSTIC MARKET: BY AGE GROUP, 2022
FIGURE 23 ASIA PACIFIC BRAIN CANCER DIAGNOSTIC MARKET: BY AGE GROUP, 2023-2030 (USD MILLION)
FIGURE 24 ASIA PACIFIC BRAIN CANCER DIAGNOSTIC MARKET: BY AGE GROUP, CAGR (2023-2030)
FIGURE 25 ASIA PACIFIC BRAIN CANCER DIAGNOSTIC MARKET: BY AGE GROUP, LIFELINE CURVE
FIGURE 26 ASIA PACIFIC BRAIN CANCER DIAGNOSTIC MARKET: BY END USER, 2022
FIGURE 27 ASIA PACIFIC BRAIN CANCER DIAGNOSTIC MARKET: BY END USER, 2023-2030 (USD MILLION)
FIGURE 28 ASIA PACIFIC BRAIN CANCER DIAGNOSTIC MARKET: BY END USER, CAGR (2023-2030)
FIGURE 29 ASIA PACIFIC BRAIN CANCER DIAGNOSTIC MARKET: BY END USER, LIFELINE CURVE
FIGURE 30 ASIA-PACIFIC BRAIN CANCER DIAGNOSTIC MARKET: SNAPSHOT (2022)
FIGURE 31 ASIA-PACIFIC BRAIN CANCER DIAGNOSTIC MARKET: BY COUNTRY (2022)
FIGURE 32 ASIA-PACIFIC BRAIN CANCER DIAGNOSTIC MARKET: BY COUNTRY (2023 & 2030)
FIGURE 33 ASIA-PACIFIC BRAIN CANCER DIAGNOSTIC MARKET: BY COUNTRY (2022 & 2030)
FIGURE 34 ASIA-PACIFIC BRAIN CANCER DIAGNOSTIC MARKET: BY TEST TYPE (2023-2030)
FIGURE 35 ASIA PACIFIC BRAIN CANCER DIAGNOSTIC MARKET: COMPANY SHARE 2022 (%)
研究方法
数据收集和基准年分析是使用具有大样本量的数据收集模块完成的。该阶段包括通过各种来源和策略获取市场信息或相关数据。它包括提前检查和规划从过去获得的所有数据。它同样包括检查不同信息源中出现的信息不一致。使用市场统计和连贯模型分析和估计市场数据。此外，市场份额分析和关键趋势分析是市场报告中的主要成功因素。要了解更多信息，请请求分析师致电或下拉您的询问。
DBMR 研究团队使用的关键研究方法是数据三角测量，其中包括数据挖掘、数据变量对市场影响的分析和主要（行业专家）验证。数据模型包括供应商定位网格、市场时间线分析、市场概览和指南、公司定位网格、专利分析、定价分析、公司市场份额分析、测量标准、全球与区域和供应商份额分析。要了解有关研究方法的更多信息，请向我们的行业专家咨询。
可定制
Data Bridge Market Research 是高级形成性研究领域的领导者。我们为向现有和新客户提供符合其目标的数据和分析而感到自豪。报告可定制，包括目标品牌的价格趋势分析、了解其他国家的市场（索取国家列表）、临床试验结果数据、文献综述、翻新市场和产品基础分析。目标竞争对手的市场分析可以从基于技术的分析到市场组合策略进行分析。我们可以按照您所需的格式和数据样式添加您需要的任意数量的竞争对手数据。我们的分析师团队还可以为您提供原始 Excel 文件数据透视表（事实手册）中的数据，或者可以帮助您根据报告中的数据集创建演示文稿。
